Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.52 |
| ▸ | CDC7 | O00311 | 2/20 | 0.46 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24215771 | 0.94 | HDAC6 (0.53) | HDAC6FLT3 | |
| SCHEMBL30409046 | 0.94 | HDAC6 (0.53) | HDAC6FLT3 | |
| SCHEMBL25353042 | 0.91 | HDAC6 (0.53) | HDAC6CDC7 | |
| SCHEMBL25993072 | 0.91 | HDAC6 (0.53) | HDAC6CDC7 | |
| SCHEMBL25352054 | 0.90 | HDAC6 (0.50) | HDAC6CDC7 | |
| SCHEMBL25347988 | 0.89 | HDAC6 (0.51) | HDAC6CDC7LRRK2 | |
| SCHEMBL25352463 | 0.89 | HDAC6 (0.49) | HDAC6 | |
| SCHEMBL25350556 | 0.89 | PSMB8 (0.43) | HDAC6PSMB8FLT3LRRK2 | |
| SCHEMBL25350810 | 0.89 | HDAC6 (0.50) | HDAC6PSMB8FLT3LRRK2 | |
| SCHEMBL25351609 | 0.88 | HDAC6 (0.53) | HDAC6FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257372-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2023-08-17 | — | — | US | disclosed |
| US-20230257372-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2023-08-17 | — | — | US | disclosed |
| US-20230257372-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2023-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257372-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HDAC6, HDAC1, HDAC3 | HDAC6 1/4885CDC7 1660/4885PSMB8 322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.